The World Health Organization (WHO) has announced the approval of the use of coronavirus vaccine created by the firm Janssen, belonging to the group Johnson & Jonhson.
Using this possible universal vaccine, also authorized by the European Medicines Agency (EMA), is intended for all countries and for their COVAX program, with which it attempts to reduce inequalities in access to covid vaccine.
This is about the first vaccine to be given in a single dose It can be kept for up to three months at a temperature between 2 and 8 degrees Celsius, two characteristics that should greatly facilitate the logistics it requires.
The director of the WHO, Tedros Adhanom Ghebreyesus, has said that this decision puts the world “one step closer to controlling the pandemic”, although he stressed that the opportunity offered by vaccines will only materialize when they are available to all people in the world. .
Characteristics of the Janssen coronavirus vaccine
According to data reviewed by WHO experts, the results of the clinical trials show that this vaccine is effective in older people.
The EMA has reported that Janssen’s vaccine is 67 percent effective against the coronavirus, according to the trials in which 44 thousand people participated in Latin America, the United States and South Africa.
Likewise, an evaluation of the quality, safety and efficacy data has been made, focused on the needs of the countries.
Beyond three months, the coronavirus vaccine must be stored at -20 degrees and its life span thus extends to two years.
From a logistical point of view, the Johnson & Johnson vaccine It is the most attractive to those of AstraZeneca, Pfizer or Moderna, since it does not require an extreme cold chain and, above all, it is single-dose.
The American pharmaceutical giant J&J had requested on February 16 the approval of the coronavirus vaccine, developed by its Janssen subsidiary.
if
– .
